Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroleptic plasma levels.

T Van Putten1, S R Marder, W C Wirshing

  • 1Veterans Affairs Medical Center, Los Angeles, CA 90073.

Schizophrenia Bulletin
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Childhood adversity and cognitive function in schizophrenia spectrum disorders and healthy controls: evidence for an association between neglect and social cognition.

Psychological medicine·2017
Same author

Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder.

Translational psychiatry·2017
Same author

Repurposing Drugs for Cognition in Schizophrenia.

Clinical pharmacology and therapeutics·2016
Same author

Efficient light emission from inorganic and organic semiconductor hybrid structures by energy-level tuning.

Nature communications·2015
Same author

Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.

European psychiatry : the journal of the Association of European Psychiatrists·2014
Same author

Adsorption studies of a phosphonic acid on ITO: film coverage, purity, and induced electronic structure changes.

Physical chemistry chemical physics : PCCP·2014
Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026
Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026
Same journal

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

The Key to Clozapine Mystery May Lie in its Shape.

Schizophrenia bulletin·2026
See all related articles

Plasma levels of antipsychotic drugs vary greatly. Therapeutic ranges are identified for some drugs, but high levels

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Therapeutics

Background:

  • Significant inter-individual variability exists in neuroleptic plasma concentrations among patients receiving identical dosages.
  • Previous research correlating antipsychotic drug plasma levels with clinical outcomes has presented interpretation challenges.
  • Treatment failure is seldom attributed to decreased bioavailability, particularly within institutional settings.

Purpose of the Study:

  • To review the clinical significance of varying plasma levels of antipsychotic medications.
  • To identify established therapeutic plasma concentration ranges for specific neuroleptics.
  • To explore the utility of monitoring antipsychotic plasma levels in complex clinical scenarios.

Main Methods:

  • Literature review and synthesis of existing research on neuroleptic plasma levels and clinical response.

Related Experiment Videos

  • Analysis of factors contributing to aberrant low or high drug concentrations.
  • Identification of tentatively established therapeutic plasma level ranges for key antipsychotic agents.

    • Main Results:

    • Therapeutic plasma level ranges have been tentatively defined for perphenazine, haloperidol, fluphenazine, and chlorpromazine.
    • Noncompliance or drug interactions (e.g., with carbamazepine) are likely causes of unusually low plasma levels.
    • The association between excessively high plasma levels and diminished treatment response remains uncertain.

    Conclusions:

    • Antipsychotic plasma level monitoring may be most valuable when differentiating between drug side effects and symptom exacerbation.
    • The clinical utility of very high neuroleptic plasma levels in treatment-resistant patients requires further investigation.
    • Understanding plasma concentration variability is crucial for optimizing antipsychotic therapy.